Associations of omega-3 fatty acids vs. fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study.

In a real-world setting, fenofibrate use was associated with a lower risk of MACE compared with low dose omega-3 fatty acids when added to statins in people with metabolic syndrome.